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Nikolaos E Tsotakos, Marina Sagnou, Eleni S Kotsopoulou, Effie C Tsilibary and Garyfalia I Drossopoulou*Abstract
Background: Renal podocytes form the main filtration barrier possessing a unique phenotype maintained by
proteins including podocalyxin and nephrin, the expression of which is suppressed in pathological conditions. We
used an in vitro model of human glomerular epithelial cells (HGEC) to investigate the role of high glucose in
dysregulating the podocytic epithelial phenotype and determined the time needed for this change to occur.
Results: In our in vitro podocyte system changes indicating podocyte dedifferentiation in the prolonged presence
of high glucose included loss of podocalyxin, nephrin and CD10/CALLA concomitant with upregulation of
mesenchymal vimentin. Our study demonstrates for the first time that podocyte-specific markers undergo changes
of expression at different time intervals, since glucose-mediated podocalyxin downregulation is a progressive
process that precedes downregulation of nephrin expression. Finally we demonstrate that high glucose
permanently impaired WT1 binding to the podocalyxin gene promoter region but did not affect WT1 binding on
the nephrin gene promoter region.
Conclusion: The presence of high glucose induced a phenotypic conversion of podocytes resembling partial
dedifferentiation. Our study demonstrates that dysregulation of the normal podocytic phenotype is an event
differentially affecting the expression of function-specific podocytic markers, exhibiting downregulation of the
epithelial marker CD10/CALLA and PC first, followed by stably downregulated nephrin. Furthermore, it is herein
suggested that WT1 may not be directly involved with upregulation of previously reduced PC and nephrin
expression.
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Glomerular visceral epithelial cells or podocytes comprise
the outermost layer of the glomerular filtration apparatus.
The podocytic slit diaphragm (SD) is a specialized cell
junction that keeps adjacent foot processes inter-
connected [1,2]. The loss of podocyte-specific proteins is
reminiscent of dedifferentiation, which has also been
described as epithelial-to-mesenchymal transition (EMT)
[3]. Tubular epithelial cells also undergo dedifferentiation
in vitro after incubation with fibrogenic TGF-β [4]. In-
jurious stimuli trigger different responses, ranging from
podocytic hypertrophy and detachment to apoptosis [3].* Correspondence: gdross@bio.demokritos.gr
Institute of Biosciences and Applications, National Centre for Scientific
Research “Demokritos”, Athens, Greece
© 2013 Tsotakos et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orUnder these pathological conditions podocytes lose
their specialized features and phenotype and may
acquire mesenchymal markers [3,5]. This has been
shown to be the case in HIV-induced nephropathy and
collapsing glomerulopathy [6] as well as TGF-β-induced
podocyte injury [7].
Pivotal podocytic markers include the antiadhesive pro-
tein podocalyxin (PC), which regulates podocyte morph-
ology, as well as foot process formation and maintenance
[8,9] and the SD-specific transmembrane protein nephrin,
which is also implicated in the pathophysiology of pro-
teinuria [10]. Glucose induces PC suppression in vivo,
in glomeruli of streptozotocin-diabetic rats [6] and
in vitro in human glomerular epithelial cells (HGEC)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glucose [12] and may be related to side-effects of
glycated albumin/AGEs [13]. The intracellular domain
of nephrin associates with CD2AP [14], an adaptor mol-
ecule which plays a major role in the maintenance of
podocyte phenotype due to its cytoskeleton stabilizing
properties [15]. A cell surface marker that has long been
considered a differentiation marker of renal epithelium
is Common Acute Lymphoblastic Leukemia Antigen
(CALLA, also called CD10) [16,17]. Another protein
used as a differentiation marker is vimentin, an intermedi-
ate filament protein characteristic of cells of mesenchymal
origin. Upregulation of its expression is considered a
major criterion for EMT [18-20] and of podocyte injury as
reported in PAN nephrosis in rats [21].
HGEC exhibit a regular cobblestone appearance in
culture and their phenotype agrees with that of parental
podocytes [11,17]. Glucose-induced PC supression in
HGEC cannot be restored by reverting glucose concen-
tration to normal levels for either short or longer time
intervals [12]. Therefore, we investigated whether HGEC
exposure to high glucose resulted in loss of the differen-
tiated podocytic characteristics and determined the time
points when this phenotypic modulation takes place.
Our results indicated that loss of PC surface expression
coincided with reduced CD10/CALLA surface levels,
while CD2AP expression was not altered. Moreover, loss of
nephrin expression accompanied the glucose-induced
downregulation of PC and CD10/CALLA, establishing that
suppression of PC surface expression occurred earlier, when
other pivotal podocytic markers were still unaffected. These
observations indicated that PC downregulation occurs in
podocytes still possessing some of their characteristics.
Results
Transient culture of HGEC in high glucose resulted in
reversible upregulation of vimentin protein expression
Vimentin is a well-known mesenchymal marker and its
upregulation is considered a significant marker of dedif-
ferentiation [19] and podocyte injury [22]. Since HGEC
permanently grown in 25 mM glucose (HGEC:25 mM)
display almost totally suppressed PC levels, compared to
HGEC exposed to 5 mM glucose (HGEC:5 mM) [12],
we examined whether this change could be attributed to
dysregulation of the podocytic phenotype, earmarked by
enhanced vimentin expression. Western blot analysis
demonstrated that vimentin expression was upregulated
in HGEC:25 mM (Figure 1A-B). Elevated vimentin
expression levels were established following 6 weeks of
culture in 25 mM glucose (HGEC:5 mM-to-25 mM/6w)
(Figure 1A-B). Vimentin expression reached maximal
levels following 18 weeks of culture (with serial pas-
sages) in 25 mM glucose (HGEC:5 mM-to-25 mM/18w)
(Figure 1A-B), suggesting that modulation of thepodocytic characteristics occurred progressively with
time. In order to determine the time points at which al-
terations in expression levels of vimentin, as well as
other important proteins expressed in podocytes oc-
curred, HGEC were exposed to 25 mM glucose for 1, 2,
4, 6, 18 weeks. From this time course an early time point
(6 weeks) and a late time point (18 weeks) were selected
in order to investigate whether glucose effects were re-
versible. The early time point was chosen because it sig-
nifies upregulation of the mesenchymal marker vimentin
and the late time point was chosen because alterations
were maximal. Accordingly, we then examined whether
the observed change in vimentin expression could be
restored to normal levels, at the early (6 weeks) time
point (HGEC:5 mM-to-25 mM/6w) and the late
(18 weeks) time point (HGEC:5 mM-to-25 mM/18w).
HGEC exposed to 25 mM glucose for 6 weeks were
reverted to normal glucose levels (5 mM) for another
4 weeks (HGEC:25 mM/6w-to-5 mM/4w). Additionally
HGEC:5 mM-to-25 mM/18w were cultured in 5 mM
glucose for 4 more weeks (HGEC:25 mM/18w-to-
5 mM/4w). In both time intervals, early and late,
vimentin reverted to lower, normal levels of expression.
In vitro culturing of HGEC in the presence of high glucose
levels resulted in permanent downregulation of CD10/
CALLA protein expression
We examined the expression of CD10/CALLA in a simi-
lar manner to vimentin. FACS analysis showed that
HGEC:5 mM expressed CD10/CALLA (Figure 1C,D).
On the contrary, HGEC:25 mM demonstrated signifi-
cantly reduced cell surface-associated levels (Figure 1C,D).
Significantly reduced CD10/CALLA surface levels were
established following 2 weeks of culture in 25 mM glucose
(HGEC:5 mM-to-25 mM/2w) (Figure 1C,D) and remained
downregulated following 6 (data not shown) and 18 weeks
of culture in 25 mM glucose (HGEC:5 mM-to-25 mM/6w,
HGEC:5 mM-to-25 mM/18w) (Figure 1C,D). CD10/
CALLA surface levels remained significantly reduced after
reverting glucose concentration to 5 mM for 18 weeks
(HGEC:25 mM-to-5 mM/18w) (Figure 1C,D). We next
examined whether the observed downregulation of CD10/
CALLA could be reversed at early (6 weeks) and late
(18 weeks) time intervals, in HGEC sequentially grown
in 5 mM glucose (HGEC:25 mM/6w-to-5 mM/4w and
HGEC:25 mM/18w-to-5 mM/4w). In both instances
CD10/CALLA remained reduced suggesting permanent
glucose-induced downregulation of its expression.
Reversible phenotypic changes of expression in cultured
podocytes are accompanied by normal levels of cell
surface-associated nephrin
HGEC:25 mM displayed severely reduced nephrin expres-
sion compared to HGEC:5 mM [11,12]. Nephrin expression
Figure 1 Vimentin and CD10/CALLA expression in podocytes. (A) Western blot analysis for vimentin expression in HGEC. Total protein was
extracted from cells cultured in the presence of 5 mM (control) (lane 1) or 25 mM (lane 2) glucose. Lane 3 represents vimentin expression in
HGEC continuously exposed to 25 mM and reverted to 5 mM glucose for 18 weeks (HGEC:25 mM-to-5 mM/18w). Lanes 4 and 5 represent HGEC
continuously exposed to 5 mM glucose and reverted to 25 mM for 6 and 18 weeks respectively (HGEC:5 mM-to-25 mM/6w, HGEC:5 mM-to-
25 mM/18w). Lanes 6 and 7 represent HGEC:25 mM/6w-to-5 mM/4w and HGEC:25 mM/18w-to-5 mM/4w respectively. For quantification of
vimentin the 57 kDa band was used. Blots were reprobed with anti-tubulin antibody, to verify protein loads, against which the data were
normalized. (B) Results were expressed as the mean ± SD of three independent experiments. (C) Representative experiments from flow
cytometric analysis of CD10/CALLA. Thick grey lines represent HGEC:5 mM, thin grey lines represent the corresponding isotype control antibody
and black lines represent stimuli. (D) Percentage of positive cells was calculated for the histogram section indicated as M1 (**p<0.01 vs.
HGEC:5 mM).
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concentration to 5 mM glucose levels [12].
Since nephrin associated with cell surface was demon-
strated to play a major role in the development ofproteinuric diseases [23], we next examined cell surface-
associated nephrin by immunocytochemical and FACS
approaches. In HGEC:5 mM-to-25 mM/4w, surface
nephrin levels were downregulated (Figure 2A,C) and
Figure 2 Nephrin cell surface expression in podocytes. (A) Confocal microscopic analysis (×600) for the distribution of nephrin in HGEC. Cells
were fixed and stained with anti-nephrin antibody and AlexaFluor 488-conjugated anti-goat IgG as secondary antibody. (B) FACS analysis of
nephrin cell surface expression. Representative experiments from flow cytometric analysis of nephrin. Thick grey lines represent HGEC 5 mM, thin
grey lines represent the corresponding isotype control antibody and black lines represent stimuli. (C) Percentage of positive cells was calculated
for the histogram section indicated as M1 (**p<0.01 vs. HGEC:5 mM).
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HGEC:5 mM-to-25 mM/18w as well as in HGEC 25 mM-
to-5 mM/18w (Figure 2). However, in HGEC:25 mM/6w-
to-5 mM/4w, and HGEC:25 mM/18w-to-5 mM/4w, cell
surface-associated nephrin was restored to normallevels, similar to those observed in HGEC:5 mM
(Figure 2). In order to verify whether these findings
were not only associated with cell surface nephrin ex-
pression but may also correspond to total protein
levels, immunoblotting experiments were performed
Figure 3 Nephrin expression in podocytes. (A) Western blot
analysis for nephrin expression in HGEC. Total protein was extracted
from cells cultured either in the presence of 5 mM (control) (lane 1) or
25 mM (lane 5) glucose. Lanes 2, 3 and 4 represent HGEC:5 mM-to-
25 mM/1w, HGEC:5 mM-to-25 mM/2w and HGEC:5 mM-to-25 mM/4w
respectively. Lane 6 represents HGEC:25 mM-to-5 mM/18w. Lanes 7
and 8 represent HGEC:25 mM/6w-to-5 mM/4w and HGEC:25 mM/18w-
to-5 mM/4w respectively. Blots were reprobed with anti-tubulin
antibody, to verify protein loads, against which the data were
normalized. (B) Results were expressed as the mean ± SD of four
independent experiments (*p<0.05 vs. HGEC:5 mM).
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analyses (Figure 3).
In vitro culturing of HGEC in high glucose transiently
reduced CD2AP expression
Western blot analysis and immunofluorescence studies
indicated that cell surface expression of CD2AP was not
affected by high glucose at 2 weeks (HGEC:5 mM-to-
25 mM/2w) (Figure 4). HGEC:5 mM and HGEC:25 mM
displayed a punctuate pattern of CD2AP expression
(Figure 4A). Significantly reduced CD2AP expression
was observed following 18 weeks of exposure to 25 mM
glucose (HGEC:5 mM-to-25 mM/18w) (Figure 4B lane 4).
However, CD2AP levels were not reduced in HGEC per-
manently grown in 25 mM glucose (HGEC:25 mM)
(Figure 4). Although CD2AP expression was not af-
fected, actin staining appeared reduced in HGEC:25 mM
and actin fibers were dysregulated (Additional file 1:
Figure S1). However, F-actin distribution could be read-
ily restored after exposure of HGEC:25 mM to normal
glucose levels for 96 hours (Additional file 1: Figure S1).Glucose-induced downregulation of PC expression is
partly reversible
Since HGEC:25 mM exhibit permanent PC expression
downregulation [12], we performed a time-course using
Western blot analysis to unravel when this phenotypic
modulation occurs. Immunoblotting experiments showed
that glucose-induced reduction of PC expression started at
2 weeks of culture in 25 mM glucose (HGEC:5 mM-to-
25 mM/2w) and maximal downregulation was observed
after 18 weeks of culture in 25 mM glucose (HGEC:5 mM-
to-25 mM/18w) (Figure 5 lanes 5,7). The extent of PC
downregulation in HGEC:5 mM-to-25 mM/2w and
HGEC:5 mM-to-25 mM/6w was statistically significant,
but PC expression levels remained higher than those
observed in HGEC:25 mM (Figure 5B lanes 1, 2, 5, 6). In
HGEC:5 mM-to-25 mM/18w, PC expression became
maximally suppressed (Figure 5B lanes 2, 7). Similar find-
ings were obtained for cell-surface PC levels, as assessed
by immunocytochemical and FACS analyses (Figure 6). In
HGEC exposed to 25 mM glucose for 6 weeks (early time
interval) and then reverted to 5 mM glucose for four more
weeks (HGEC:25 mM/6w-to-5 mM/4w), PC expression
was totally restored (Figure 5A,B). On the contrary, HGEC
cultured in 25 mM glucose for 18 weeks (late time interval)
and reverted to normal glucose (5 mM) for four more
weeks (HGEC:25 mM/18w-to-5 mM/4w) did not
upregulate PC expression (Figure 5A,B). These observa-
tions were confirmed by FACS and immunofluorescence
analyses (Figure 6). The observed effects were specifically
due to D-glucose and not to any osmotic effect, because
immunoblotting analysis of cells grown in 25 mM L-
glucose revealed no changes in protein levels. The induced
suppression was specific to PC, since other inter-related
proteins such as α3β1-integrins were also decreased by high
glucose, but their levels were immediately restored when
glucose levels were reverted to 5 mM (Additional file 2:
Figure S2).
High glucose impaired binding of WT1 to the PC
promoter
WT1 binding elements have been identified on the pro-
moter of PC gene (podxl) [24,25]. ChIP followed by
quantitative PCR showed that WT1 binding to podxl
promoter region in HGEC:25 mM was decreased by
>50% compared to HGEC:5 mM (Figure 6A columns
corresponding to 5 mM and 25 mM). In agreement with
the observed permanent reduction of PC expression,
binding of WT1 to the podxl promoter was also reduced
when HGEC:25 mM which do not express PC were
reverted to normal glucose for as long as 18 weeks
(HGEC:25 mM-to-5 mM/18w) (Figure 7A). Although in
HGEC:25 mM-to-5 mM/18w the binding of WT1 to the
podxl promoter appeared relatively increased compared
to that observed in HGEC:25 mM, the increase was not
Figure 4 CD2AP expression in podocytes. (A) Confocal microscopic analysis (×600) for the distribution of CD2AP in HGEC. Cells were fixed and
stained with anti-CD2AP antibody and AlexaFluor 488-conjugated anti-mouse IgG as secondary antibody. (B) Western blot analysis for CD2AP
expression in HGEC. Total protein was extracted from HGEC:5 mM (control) (lane 1) or HGEC:25 mM (lane 4). Lanes 2 and 3 represent CD2AP
expression in HGEC:5 mM-to-25 mM/2w and HGEC:5 mM-to-25 mM/18w respectively. Lane 5 represents CD2AP expression in HGEC:25 mM-to-
5 mM/18w. Blots were reprobed with anti-tubulin antibody, to verify protein loads, against which the data were normalized. (C) Results were
expressed as the mean ± SD of three independent experiments (*p<0.05 vs. HGEC:5 mM).
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5 mM/18w binding of RNA polymerase to the relative
promoter region remained reduced. HGEC exposed to
25 mM glucose for 6 weeks (HGEC:5 mM-to-25 mM/6w)
displayed a 2-fold reduction of binding of WT1 to podxl
promoter (Figure 7A), to an extent similar to that ob-
served in HGEC:5 mM-to-25 mM/18w and to that ob-
served in 25 mM glucose (Figure 7A). We then examined
whether reduced WT1 binding to podxl promoter could
be reversed at early (6 weeks) and late (18 weeks) time
points. Even though PC expression at the early time point
was restored, the binding of WT1 to podxl promoter
remained decreased (Figure 5 lane 8 and Figure 7A). At
the late time point, a partial but non-significant increase
of WT1 binding to podxl promoter was observed that was
not however associated with restoration of PC expression
(Figure 5 lane 9 and Figure 7A).
WT1 binding to the nphs1 promoter is not affected by
high glucose
In addition to the PC promoter, WT1 binds to the nephrin
gene (nphs1) promoter and activates nephrin expressionin podocytes [26]. ChIP followed by quantitative real-time
PCR showed that binding of WT1 to the nphs1 promoter
was significantly reduced when HGEC:25 mM which
do not express PC were reverted to normal glucose for
as long as 18 weeks (HGEC 25 mM-to-5 mM/18w)
(Figure 7B). However, there were no significant differ-
ences in WT1 binding to the nphs1 promoter in
HGEC:5 mM (expressing nephrin) or HGEC permanently
exposed to high glucose (HGEC:25 mM, not expressing
nephrin). These results indicate that downregulation and
restoration of cell surface-associated nephrin was not ac-
companied by altered binding of WT1 to the relevant gene
promoter (Figure 7B).
Discussion
The glomerular podocyte is believed to play a role in
the development and progression of albuminuria and
glomerulosclerosis associated with diabetes, among other
[27,28]. Podocytes, and more particularly dysregulation of
their differentiation, amongst other injurious stimuli, are
at the centre of the pathogenesis of nephropathy. In this
study, we describe the gradual modulation of pivotal
Figure 5 PC expression in podocytes. (A) Western blot analysis
for PC expression in HGEC. Total protein was extracted from cells
cultured either in the presence of 5 mM (control) (lane 1) or 25 mM
(lane 2) glucose. Lane 3 represents PC expression in HGEC:25 mM-
to-5 mM/18w. Lanes 4, 5, 6 and 7 represent HGEC:5 mM-to-25 mM/
1w, HGEC:5 mM-to-25 mM/2w, HGEC:5 mM-to-25 mM/6w and
HGEC:5 mM-to-25 mM/18w respectively. Lanes 8 and 9 represent
HGEC:25 mM/6w-to-5 mM/4w and HGEC:25 mM/18w-to-5 mM/4w
respectively. Blots were reprobed with anti-tubulin antibody, to
verify protein loads, against which the data were normalized.
(B) Results were expressed as the mean ± SD of four independent
experiments (*p<0.05 vs. HGEC:5 mM, **p<0.01 vs. HGEC:5 mM,
#p<0.05 vs. HGEC:25 mM).
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sponse to chronic exposure to high glucose. This conver-
sion could be considered as a dedifferentiation process,
since it was accompanied by increased expression of mes-
enchymal vimentin and reduced expression of specialized
epithelial components which are podocytic markers. Our
data indicated that glucose-mediated PC downregulation
which occurred progressively, preceded downregulation of
nephrin, the expression of which was substantially
suppressed as early as 4 weeks of culture in high glucose.
Changes of podocyte structure and function have been
previously described as epithelial-to-mesenchymal tran-
sition (EMT) [29-31] since pro-fibrotic components
appeared, concomitant with loss of markers characteristicof epithelial differentiation. However, phenotypic changes
of podocytes observed in vitro or in vivo may not neces-
sarily represent EMT-like changes [18]. Podocytes are cells
embryonically derived from the metanephric mesenchyme
and express epithelial markers (e.g. ZO-1, cytokeratin).
Following exposure to TGF-β1, epithelial markers of
podocytes were reported to be increased, concomitant
with increased tight junction formation [32]. In contrast,
in EMT tight junctions are reduced. The phenotypic
changes observed in our in vitro model more closely
resemble a process of partial dedifferentiation. Vimentin, a
component of intermediate filaments is expressed in
differentiated podocytes but its expression becomes
upregulated in podocytes lacking their specific markers,
for example in nephrotic glomeruli, in the puromycin
aminonucleoside model in rat [22]. Hence enhanced
vimentin expression in podocytes following chronic ex-
posure to high glucose could represent a marker of dedif-
ferentiation. Partial podocyte dedifferentiation induced by
high glucose could be further supported by the observed
loss of PC, nephrin and CALLA, concomitant with
upregulation of mesenchymal vimentin.
Our findings are consistent with the reported effects of
TGF-β1 and Ang-II resulting in podocyte dedifferentiation
and apoptosis under normal and high glucose conditions
[7,33-35]. Additionally, our study demonstrates for the
first time that dysregulation of the normal podocytic
characteristics is an event differentially affecting the
expression of function-specific podocytic markers:
downregulation of the epithelial marker CD10/CALLA
and PC first occurred progressively, and were followed
by stably downregulated nephrin at later time
intervals.
Nephrin and CD2AP are pivotal for slit diaphragm
permselective properties [29,36], and their loss has been
linked to podocytic dysregulation and loss of the differ-
entiated podocytic phenotype [37]. The punctate pattern
of expression of nephrin and CD2AP which was ob-
served in our in vitro system of podocytes (Figures 2, 4)
could represent the in vitro equivalent of foot-like
process formation [11]. Accordingly, glucose-induced,
decreased punctate staining in these cells [11] possibly
indicated the existence of fewer foot-like processes, re-
sembling foot effacement in vivo. Downregulation of the
podocyte marker nephrin concomitant with upregulation
of the mesenchymal marker vimentin occurred following
4 weeks of exposure to high glucose. Glucose-mediated
downregulation of PC expression started as early as two
weeks following exposure to high glucose, and gradually
reached maximal suppression within 18 weeks. Hence,
glucose-induced loss of the differentiated characteristics
was complete by 18 weeks. In other studies, in human
lung adenocarcinoma, PC downregulation appeared to
be intimately associated with upregulation of vimentin
Figure 6 PC cell surface expression in podocytes. (A) Confocal microscopic analysis (×600) for the distribution of PC in HGEC. Cells were fixed
and stained with anti-PC antibody and AlexaFluor 488-conjugated anti-mouse IgG as secondary antibody. (B) FACS analysis of PC cell surface
expression. Representative experiments from flow cytometric analysis of PC. Thick grey lines represent cells HGEC:5 mM, thin grey lines represent
the corresponding isotype control antibody and black lines represent stimuli. (C) Percentage of positive cells was calculated for the histogram
section indicated as M1 (*p<0.05 vs. HGEC:5 mM, **p<0.01 vs. HGEC:5 mM, #p<0.05 vs. HGEC:25 mM).
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[38]. We herein report for the first time that in in vitro
cultured podocytes, PC downregulation was reversible
only when the cells still expressed this component in sub-
stantial, albeit decreased amounts. At later time intervals,
the observed maximal loss of PC became permanent. Inagreement with our observations, in an in vivo mouse
model of podocyte injury, the decrease in nephrin and
synaptopodin reflected early downregulation of these pro-
teins in injured but still functioning podocytes, but PC ex-
pression was substantially downregulated only in severely
injured or sclerotic podocytes [39].
Figure 7 ChIP analysis of WT1 binding to podxl and nphs1
promoter regions. (A) WT1 binds cis regions of podxl gene
promoter in HGEC. Formaldehyde-crosslinked chromatin fragments
were precipitated with either anti-WT1 antibody, anti-RNA
polymerase II or no antibody as mock. Precipitated products were
amplified by real-time PCR using primers for podxl proximal
promoter. As normalizer, a DNA fragment lacking any WT1 site,
located in the promoter region of GAPDH gene, was used. (B) WT1
binds cis regions of nphs1 gene promoter in HGEC. Formaldehyde-
crosslinked chromatin fragments were precipitated with either anti-
WT1 antibody, anti-RNA polymerase II or no antibody as mock.
Precipitated products were amplified by real-time PCR using primers
for nphs1 promoter. As normalizer, a DNA fragment lacking any WT1
site, located in the promoter region of GAPDH gene, was used.
(*p<0.05 vs. HGEC:5 mM, #p<0.05 vs. HGEC:25 mM).
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tion that restoration of PC expression was not WT1-
mediated, since this process was not accompanied by
restoration of WT1 binding to the PC gene promoter
region. Earlier in vivo and in vitro studies reported that
increased levels of expression and activity of WT1 were
associated with increased levels of PC expression in
podocytes [25,40]. However, it has been proposed that
WT1 alone does not suffice to upregulate PC expression
[12,41]. Our observations suggest that WT1 is impli-
cated in establishing basal PC levels and maintaining PC
expression in differentiating and differentiated podocytes
[25]; nevertheless according to our data WT1 was not
directly involved with upregulation of previously reduced
PC expression. Moreover, at the late time interval, when
PC downregulation had become permanent, a minor
(but non-significant) increase of WT1 binding at the
relative response element was observed which was not
adequate for transcriptional activation. Additional
transcription factors could be apparently involved in
re-starting the partially or permanently suppressed ex-
pression of PC in the presence of high glucose. In this
instance, WT1 may function in a manner similar to
that used for regulation of the expression of the nephrin
gene, since downregulation and re-expression of cell
surface-associated nephrin were not accompamied by
altered binding of WT1 to the nephrin gene promoter.
Interestingly, it has been suggested that the Sp1 zinc finger
protein can support transcriptional regulation of either
nephrin or PC independently of WT1 [41,42]. Another
transcription factor implicated in upregulation of nephrin
[43] and PC expression (unpublished data) is the vitamin
D receptor (VDR), strongly indicating that enhancement
of nephrin and PC expression may be WT1 independent.
Conclusions
Chronic exposure to high glucose induced a phenotypic
conversion of cultured podocytes resembling dedifferen-
tiation. This dedifferentiation process was gradual and
progressive, first started with loss of the differentiation
markers CD10/CALLA and PC, and was followed by
enhanced vimentin and markedly reduced nephrin ex-
pression. Reversible upregulation of vimentin expression
was associated with restoration of normal nephrin ex-
pression. However, PC downregulation was irreversible
when maximal loss of PC had been established. These
observations indicate that attenuation of PC expression
was mainly glucose dependent and persisted in HGEC
possessing podocytic characteristics. Dumpening of PC
expression could be thus considered a reliable marker of
podocytic injury and partial dedifferentiation. Therefore,
rescuing PC expression may be pivotal in hyperglycemic
conditions such as diabetic nephropathy. However this
needs to be verified by in vivo studies. Finally, our data
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differentiated podocytic phenotype does not necessarily
involve WT1, which however is crucial for the process of
differentiation of podocytic presursors to podocytes.
Hence, investigating the role of other transcription factors
in preserving and restoring structural and functional
integrity of the podocytes is of paramount importance.Methods
Cell line and culture conditions in different glucose
concentrations
Immortalized T-SV40 HGEC were cultured in the pres-
ence of 5 or 25 mM glucose as previously described
[11,12]. Cells were released from their culture flasks for
passaging by treatment with 0.05% trypsin/0.03% EDTA
when they reached 80% confluency. Glucose concentra-
tion in the culture medium was adjusted as previously
described [12]. Briefly, culturing of immortalized T-SV40
HGEC in the presence of 5 mM glucose was followed by a
growing period in the presence of 25 mM with serial pas-
sages. During this period the culture medium was changed
every 48 hours, with fresh medium containing 25 mM glu-
cose. The duration of this period was up to 18 weeks
(HGEC:5-to-25 mM/18w) and a batch of cells was stored
in liquid nitrogen once every 2 weeks for the entire period.
At the end of the incubation period, the cells were
released by trypsin-EDTA from their culture flasks and
subsequently used for experiments. Moreover, cell cultures
that completed a growing period of 6- or 18- weeks were
subsequently plated in tissue culture flasks and allowed to
grow in the presence of 5 mM glucose for 4 more weeks
(HGEC:25 mM/6w-to-5 mM/4w, HGEC:25 mM/18w-to-
5 mM/4w). During this period the culture medium was
changed every 48 hours, with fresh medium containing
5 mM glucose. At the end of culture period, cells were
released from their flask and used for the relevant
experiment.Western blotting
Cultured cells were released by trypsin treatment. For
total PC and vimentin expression cells were lysed in
modified buffer as described previously [11,12]. For
total nephrin expression cells were lysed in RIPA buf-
fer. For α3 β1 protein expression cells were lysed in a
buffer containing 1% Triton X-100, 1 mM CaCl2 as
described previously [44]. Protein determination was
performed by the Bradford assay (Pierce). For Western
blot analysis, 50 μg-100 μg protein from cell lysates
were run on 7.5% SDS-PAGE. Proteins were then
transferred to Hybond-ECL nitrocellulose membrane
(Amersham) for immunoblotting according to previ-
ously described procedures [12].Flow cytometry (FACS) analysis
Cells were cultured as described, released from their
dishes by trypsin treatment, washed with PBS and
resuspended in FACS buffer (2% non-heat inactivated
FCS in PBS). Cells were incubated with the following
antibodies overnight at 4°C; goat anti-nephrin (C-17,
Santa Cruz Biotechnology, 1:50), mouse anti-pclp (3D3,
Santa Cruz Biotechnology, 1:50) and mouse anti-CD10
(cd-calla, Santa Cruz Biotechnology, 1 μg/106 cells).
After washes with FACS buffer cells were incubated with
the appropriate Alexa Fluor 488-conjugated secondary
antibodies (Invitrogen, 1:1000) and fixed with 1%
formaldehyde in PBS. Analysis was performed using Cell
Quest Software on a FACScan (Becton Dickinson). To
omit debris and cell clumps, gating was performed and
104 gated events were counted. The number of positive
cells was calculated in the histogram section selected by
the M1 marker in order to subtract the fluorescence of
negative control (cells incubated only with the secondary
antibody).
Immunofluorescence
Immunofluorescence studies were performed as described
previously [45]. Briefly, coverslip-attached HGEC were
fixed in 3.6% paraformaldehyde containing 2% D-sucrose
for 15 minutes at room temperature and washed with
PBS. For localization of nephrin and CD2AP, cells were
permeabilized with HEPES/Triton X-100 buffer (20 mM
HEPES, 300 mM D-sucrose, 50 mM NaCl, 3 mM MgCl2,
0.5% Triton X-100) for 5 minutes at 4°C; for localization
of PC, cells were made permeable with a solution of 0.5%
Triton X-100 for 15 minutes at 4°C. Cells were then in-
cubated overnight at 4°C with the following primary
antibodies; goat anti-nephrin (C-17, Santa Cruz Bio-
technology, 1:20), mouse anti-CD2AP (B-4, Santa Cruz
Biotechnology, 1:200), mouse anti-PC (3D3, Santa Cruz
Biotechnology, 1:15). After rinsing, slides were incu-
bated with appropriate Alexa Fluor 488-conjugated sec-
ondary antibodies (Invitrogen, 1:100) for 1 hour at
room temperature, mounted with Vectashield mounting
medium and examined. For double staining for CD2AP
and actin cells were permeabilized with HEPES/Triton
X-100 buffer (20 mM HEPES, 300 mM D-sucrose,
50 mM NaCl, 3 mM MgCl2, 0.1% Triton X-100) for
5 minutes at room temperature. Cells were then incu-
bated overnight at 4°C with Texas Red phalloidin
(1:100) and mouse anti-CD2AP (1:200) in PBS, 1% calf
serum. After rinsing, slides were incubated with the
appropriate Alexa Fluor 488-conjugated secondary anti-
body for CD2AP.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays were performed
with the use of EZ ChIP Chromatin Immunoprecipitation
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protocol. HGEC were grown on 10 cm plates until 85%
confluency. Proteins were cross-linked to DNA by incu-
bating the cells with 1% formaldehyde in culture medium
for 20 minutes at room temperature. Cross-linking was
stopped by adding 0.125 M glycine for 5 minutes at room
temperature. Cells were collected in PBS containing prote-
ase inhibitors cocktail II and centrifuged for 5 minutes at
2000 g at 4°C. Cell pellets were dissolved in 150 mM NaCl,
50 mM Tris pH 8.0, 5 mM EDTA, 0.5% NP-40 and 1%
Triton X-100. Nuclei were collected by centrifugation at
12000 g for 5 minutes at 4°C and were suspended in
sonication buffer containing 50 mM HEPES, 140 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium
deoxycholate, 0.1% SDS and protease inhibitor cocktail II.
Aliquots of 350 μl were sonicated in a cold ethanol bath
(4 × 5 minutes at 21% intensity with on/off cycles of
30 seconds) with a Sonics Vibra-Cell VCX 750 (Sonics
& Materials, Inc.) to an average length of 500 bp and
centrifuged at 15000 g for 15 minutes at 4°C. Aliquots
of supernatant (100 μl) were incubated overnight at 4°C
with 1.2 μg of rabbit anti-WT1 antibody (C19, Santa
Cruz Biotechnology), 1.0 μg anti-RNA polymerase II
(CTD4H8) or in the absence of antibody. 1% of non-
immunoprecipitated chromatin was saved as input sam-
ple. After dilution in ChIP dilution buffer, immune
complexes were collected by adsorption to protein G-
coupled agarose beads for 2 h at 4°C. After stringent
washing protein/DNA complexes were eluted from the
beads with incubation in 1% SDS, 100 mM NaHCO3 for
15 minutes at room temperature. Cross-links between
proteins and DNA were reversed by addition of
200 mM NaCl and overnight incubation at 65°C. Fol-
lowing degradation of RNA and proteins, DNA was
purified using spin columns. Quantitative amplification
of precipitated DNA fragments was performed on a
Stratagene Mx3000P system using SYBR Green in tripli-
cate. As normalizer, a DNA fragment lacking any WT1
site was used, located in the promoter region of GAPDH
gene. The following primer pairs were used; PC promoter:
5′-TTAATAGATTGGCACAGTTAGG–3′, 5′– GAGAG
AAGTTTGGAGAAATACC–3′; nphs1 promoter: 5′-
CGCCCAGTCTCTTTATCTTTC–3′, 5′–GACAAGGA
GCAGGAGTGAG– 3′; GAPDH promoter: 5′–TACTA
GCGGTTTTACGGGCG–3′, 5′–CGAACAGGAGGAGC
AGAGAGCGA-3′. Fold-change in gene promoter site
occupancy was calculated as described elsewhere [46].
Statistical analysis
Results are expressed as means ± SD. Mean values were
derived from experiments performed at least three times.
Single-factor ANOVA was used to evaluate the results of
Western blotting, FACS assays, and ChIP assays. Add-
itionally, post hoc testing using the Newman-Keuls testwas used to compare the differences between the
selected pairs of means. In all instances, p<0.05 was
considered statistically significant.
Additional files
Additional file 1: Figure S1. CD2AP and F-actin colocalization in
podocytes. Confocal microscopic analysis for the distribution of CD2AP
and F-actin in HGEC. Cells were fixed and stained with Texas Red
Phalloidin (red) and anti-CD2AP antibody.
Additional file 2: Figure S2. α3 β1-integrin expression in podocytes.
(A) Western blot analysis for α3 β1-integrin expression in HGEC. Blots
were reprobed with anti-tubulin antibody, to verify protein loads, against
which the data were normalized. (B) Results were expressed as the mean ±
SD of three independent experiments (*p<0.05 vs. HGEC:5 mM, #p<0.05 vs.
HGEC:25 mM).
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